Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Research & Development data on file, last reported at $19.3 million in Q1 2026.

• On a quarterly basis, Research & Development rose 13.25% year-over-year to $19.3 million in Q1 2026; TTM through Mar 2026 was $71.8 million, a 27.7% increase from a year earlier, with the FY2025 full-year figure at $69.5 million, up 38.17% from the prior year.
• Research & Development for Q1 2026 stood at $19.3 million, up from $17.0 million in the prior quarter.
• Over the last five years, Research & Development for ARTV reached as high as $19.3 million in Q1 2026 and fell as low as $11.2 million in Q4 2023.
• Historically, Research & Development has averaged $14.6 million across 4 years, with a median of $13.4 million in 2024.
• Across the five-year window, Research & Development rose 3.51% in 2024 and jumped 52.85% in 2025, its largest moves.
• Year by year, Research & Development stood at $11.2 million in 2023, then rose by 19.4% to $13.3 million in 2024, then increased by 27.61% to $17.0 million in 2025, then increased by 13.64% to $19.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $19.3 million in Q1 2026, $17.0 million in Q4 2025, and $17.6 million in Q3 2025.